Total Payments
$644,789
2023 Payments
$3,182
Companies
59
Transactions
1,365
Medicare Patients
3,765
Medicare Billing
$913,248
Payment Breakdown by Category
Other$291,927 (45.3%)
Consulting$251,518 (39.0%)
Travel$78,627 (12.2%)
Food & Beverage$22,570 (3.5%)
Education$146.92 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $284,042 | 92 | 44.1% |
| Consulting Fee | $251,518 | 117 | 39.0% |
| Travel and Lodging | $78,627 | 283 | 12.2% |
| Food and Beverage | $22,570 | 861 | 3.5% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $6,500 | 2 | 1.0% |
| Honoraria | $1,385 | 2 | 0.2% |
| Education | $146.92 | 8 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Daiichi Sankyo Inc. | $176,816 | 203 | $0 (2023) |
| Eli Lilly and Company | $160,363 | 6 | $0 (2017) |
| PFIZER INC. | $83,391 | 213 | $0 (2023) |
| Edwards Lifesciences Corporation | $62,393 | 100 | $0 (2021) |
| Amgen Inc. | $33,480 | 53 | $0 (2023) |
| Synergy Pharmaceuticals Inc | $21,879 | 52 | $0 (2018) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $20,904 | 1 | $0 (2018) |
| E.R. Squibb & Sons, L.L.C. | $12,078 | 10 | $0 (2022) |
| Shire North American Group Inc | $11,639 | 16 | $0 (2019) |
| RedHill Biopharma Inc. | $10,320 | 34 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $3,182 | 68 | Ardelyx, Inc. ($2,028) |
| 2022 | $26,281 | 171 | Amgen Inc. ($15,472) |
| 2021 | $39,988 | 153 | Amgen Inc. ($17,877) |
| 2020 | $31,166 | 131 | Edwards Lifesciences Corporation ($26,731) |
| 2019 | $61,377 | 194 | Edwards Lifesciences Corporation ($30,198) |
| 2018 | $154,823 | 327 | Daiichi Sankyo Inc. ($52,698) |
| 2017 | $327,972 | 321 | Eli Lilly and Company ($160,363) |
All Payment Transactions
1,365 individual payment records from CMS Open Payments — Page 1 of 55
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/28/2023 | Ardelyx, Inc. | IBSRELA (Drug) | Consulting Fee | Cash or cash equivalent | $1,875.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 07/13/2023 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $21.28 | General |
| Category: GASTROENTEROLOGY | ||||||
| 06/29/2023 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $21.71 | General |
| Category: IMMUNOLOGY | ||||||
| 06/24/2023 | Pharmacosmos Therapeutics Inc. | MONOFERRIC (Drug) | Food and Beverage | In-kind items and services | $23.20 | General |
| Category: HEMATOLOGY | ||||||
| 06/22/2023 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $22.77 | General |
| Category: INTERNAL MEDICINE | ||||||
| 06/22/2023 | Alnylam Pharmaceuticals Inc. | GIVLAARI (Drug) | Food and Beverage | In-kind items and services | $13.37 | General |
| Category: Genetic Disease | ||||||
| 06/20/2023 | INTERCEPT PHARMACEUTICALS, INC. | OCALIVA (Drug) | Food and Beverage | In-kind items and services | $19.81 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 06/13/2023 | Amgen Inc. | AMJEVITA (Biological), AVSOLA | Food and Beverage | In-kind items and services | $20.50 | General |
| Category: Inflammation | ||||||
| 06/13/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $13.12 | General |
| Category: Gastroenterology | ||||||
| 06/12/2023 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $14.50 | General |
| Category: Iron Deficiency Anemia | ||||||
| 06/07/2023 | PFIZER INC. | XELJANZ (Drug), PAXLOVID | Food and Beverage | In-kind items and services | $20.29 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 06/06/2023 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $27.17 | General |
| Category: Immunology | ||||||
| 06/06/2023 | ABBVIE INC. | LINZESS (Drug) | Food and Beverage | In-kind items and services | $9.65 | General |
| Category: GASTROENTEROLOGY | ||||||
| 05/31/2023 | Merck Sharp & Dohme LLC | DIFICID (Drug), ZINPLAVA | Food and Beverage | In-kind items and services | $15.52 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 05/30/2023 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $14.53 | General |
| Category: IMMUNOLOGY | ||||||
| 05/22/2023 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $18.88 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 05/18/2023 | Micro-tech Endoscopy USA, Inc. | Blue Boost (Device) | Food and Beverage | Cash or cash equivalent | $28.15 | General |
| Category: GI Endoscopy | ||||||
| 05/11/2023 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $20.84 | General |
| Category: VIROLOGY | ||||||
| 05/10/2023 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $20.07 | General |
| Category: GASTROENTEROLOGY | ||||||
| 05/04/2023 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $16.99 | General |
| Category: IMMUNOLOGY | ||||||
| 05/03/2023 | PFIZER INC. | XELJANZ (Drug), PAXLOVID | Food and Beverage | In-kind items and services | $20.29 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 05/01/2023 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $17.21 | General |
| Category: Immunology | ||||||
| 04/28/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $17.93 | General |
| 04/27/2023 | ABBVIE INC. | LINZESS (Drug) | Food and Beverage | In-kind items and services | $26.23 | General |
| Category: GASTROENTEROLOGY | ||||||
| 04/25/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $22.02 | General |
| Category: Neuroscience | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 453 | 3,909 | $441,466 | $102,129 |
| 2022 | 19 | 1,035 | 10,708 | $992,852 | $275,490 |
| 2021 | 21 | 1,204 | 10,894 | $960,721 | $296,146 |
| 2020 | 22 | 1,073 | 7,665 | $829,170 | $239,482 |
Total Patients
3,765
Total Services
33,176
Medicare Billing
$913,248
Procedure Codes
71
All Medicare Procedures & Services
71 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 59 | 3,484 | $178,067 | $62,032 | 34.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 124 | 147 | $51,156 | $12,539 | 24.5% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 45 | 45 | $47,610 | $8,446 | 17.7% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 32 | 32 | $45,632 | $6,910 | 15.1% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 60 | 62 | $69,688 | $5,195 | 7.5% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 20 | 21 | $31,500 | $3,421 | 10.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 40 | 41 | $9,717 | $2,552 | 26.3% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 62 | 66 | $5,346 | $773.50 | 14.5% |
| 91200 | Measurement of liver stiffness | Office | 2023 | 11 | 11 | $2,750 | $260.50 | 9.5% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 97 | 9,540 | $431,595 | $161,999 | 37.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 287 | 367 | $107,740 | $34,627 | 32.1% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2022 | 73 | 73 | $68,302 | $14,348 | 21.0% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 60 | 62 | $64,076 | $13,411 | 20.9% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 104 | 104 | $103,680 | $8,674 | 8.4% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2022 | 37 | 37 | $38,134 | $7,326 | 19.2% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 50 | 50 | $55,744 | $7,236 | 13.0% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2022 | 37 | 39 | $30,443 | $5,885 | 19.3% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 15 | 41 | $30,200 | $4,987 | 16.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 29 | 32 | $11,321 | $4,357 | 38.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 32 | 32 | $7,274 | $2,386 | 32.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 19 | 19 | $7,600 | $2,267 | 29.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 99 | 162 | $10,686 | $1,997 | 18.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 19 | 19 | $5,038 | $1,508 | 29.9% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 16 | 30 | $2,868 | $1,479 | 51.6% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 15 | 15 | $8,490 | $1,338 | 15.8% |
About Dr. Michael Epstein, M.D
Dr. Michael Epstein, M.D is a Gastroenterology healthcare provider based in Annapolis, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/29/2006. The National Provider Identifier (NPI) number assigned to this provider is 1942238928.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Epstein, M.D has received a total of $644,789 in payments from pharmaceutical and medical device companies, with $3,182 received in 2023. These payments were reported across 1,365 transactions from 59 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($284,042).
As a Medicare-enrolled provider, Epstein has provided services to 3,765 Medicare beneficiaries, totaling 33,176 services with total Medicare billing of $913,248. Data is available for 4 years (2020–2023), covering 71 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Annapolis, MD
- Active Since 06/29/2006
- Last Updated 02/19/2015
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1942238928
Products in Payments
- INJECTAFER (Drug) $176,834
- INFLECTRA (Biological) $57,317
- AVSOLA (Biological) $33,430
- Trulance (Drug) $21,879
- XELJANZ (Drug) $14,220
- ZEPOSIA (Drug) $12,705
- Talicia (Drug) $10,097
- XIFAXAN (Drug) $5,600
- AspireAssist System (Device) $4,342
- PREPOPIK (Drug) $2,788
- VIBERZI (Drug) $2,518
- IBSRELA (Drug) $2,160
- PLENVU (Drug) $1,650
- STELARA (Biological) $993.82
- Monoferric (Drug) $875.96
- Humira (Biological) $785.64
- MONOFERRIC (Drug) $623.58
- HUMIRA (Biological) $601.73
- Symproic (Drug) $575.00
- LINZESS (Drug) $509.65
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Annapolis
Dr. Raja Taunk, M.d, M.D
Gastroenterology — Payments: $347,396
Gastroenterology $347,396
Dr. Mark Flasar, M.d, M.D
Gastroenterology — Payments: $155,798
Gastroenterology $155,798
Dr. Kevin Wolov, D.o, D.O
Gastroenterology — Payments: $31,103
Gastroenterology $31,103
Dr. Vishnupriya Krishna, Md, MD
Gastroenterology — Payments: $17,302
Gastroenterology $17,302
Dr. Charles King, M.d, M.D
Gastroenterology — Payments: $7,579
Gastroenterology $7,579
Dr. Barry Cukor, Md, MD
Gastroenterology — Payments: $7,253
Gastroenterology $7,253